Clinical Trial Update: Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update of dasatinib in pediatric patients with Philadelphia chromosome–positive leukemia or recurrent/refractory solid tumors, including …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia | Phase 1 | Status: COMPLETED